Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $73.58M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 5.42M
Average 3.79M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Enanta Pharmaceuticals, Inc. NASDAQ:ENTA | $320.09M | $10.99 | Not rated | -4.3 | -29.69% |
Nautilus Biotechnology, Inc. NASDAQ:NAUT | $295.50M | $2.32 | Not rated | -4.9 | +6.79% |
Prelude Therapeutics Incorporated NASDAQ:PRLD | $275.32M | $3.45 | Not rated | -4.5 | +97.62% |
Immuneering Corporation NASDAQ:IMRX | $240.27M | $3.71 | Not rated | -3.6 | -51.61% |
Humacyte, Inc. NASDAQ:HUMA | $155.12M | $0.56 | Not rated | -1.9 | -58.25% |
Abeona Therapeutics Inc. NASDAQ:ABEO | $138.30M | $2.42 | Not rated | 4.9 | -41.96% |
Foghorn Therapeutics Inc. NASDAQ:FHTX | $124.12M | $2.07 | Not rated | -3.8 | -63.55% |
Voyager Therapeutics, Inc. NASDAQ:VYGR | $107.66M | $1.73 | Not rated | -1.9 | -64.49% |
Pyxis Oncology, Inc. NASDAQ:PYXS | $100.10M | $1.58 | Not rated | -1.6 | -69.49% |
Caribou Biosciences, Inc. NASDAQ:CRBU | $39.10M | $0.36 | Not rated | -1.1 | -73.83% |
Continue the stock analysis
Jump to another research area for this company.